'We are pleased to be part of the Thrive-IVF Research Study to help evaluate a unique treatment option that could help improve pregnancy success rates and outcomes for women who have undergone multiple unsuccessful IVF procedures,' said Eric A. Widra, MD.
Rockville, MD (PRWEB) August 13, 2013
Shady Grove Fertility today announced its participation in the Thrive-IVF Research Study, a Phase 2 clinical trial sponsored by Nora Therapeutics, Inc., to evaluate the efficacy, safety and tolerability of NT100 in women who have had repeated in vitro fertilization (IVF) failures despite having good quality embryos. A novel biologic agent similar to a naturally occurring protein in the female reproductive tract, NT100 is being specifically designed and developed for use following in vitro fertilization (IVF) procedures to improve pregnancy success rates and outcomes.
“We are pleased to be part of the Thrive-IVF Research Study to help evaluate a unique treatment option that could help improve pregnancy success rates and outcomes for women who have undergone multiple unsuccessful IVF procedures,” said Shady Grove Fertility’s Eric A. Widra MD, Thrive-IVF study investigator.
More than seven million couples in the US suffer from infertility and 10 percent of women of childbearing age in the developed world experience infertility in any given 12-month period. While significant research efforts in IVF have been focused on the embryo, it is estimated that three-fourths of all embryos that are transferred still fail to implant in the uterus.
A critical part of the equation for the establishment and maintenance of a successful pregnancy is the presence not only of a good embryo, but also a favorable maternal environment for the embryo to implant and thrive. NT100’s novel mechanism of action may better enable embryo implantation and pregnancy maintenance by optimizing maternal-fetal immune tolerance. There are currently no FDA-approved therapies focused on this critical dimension of endometrial receptivity.
“Nora believes that Shady Grove Fertility is an ideal partner for this important infertility study,” said Jeffrey K Tong, Ph.D., President and CEO, Nora Therapeutics. “We are excited to advance our NT100 clinical program with the goal of generating the evidence needed to earn FDA approval as the first and only treatment indicated to improve pregnancy success rates and outcomes for women with a history of repeated IVF failures.”
About the Thrive-IVF Research Study
The Thrive-IVF Research Study (NT-03) is a randomized, double-blind, multi-center, placebo-controlled study to evaluate the efficacy, safety and tolerability of NT100 in approximately 150 women 21-38 years of age who have had repeated (three or more) IVF failures despite having good-quality embryos. Study participants will be randomized to receive NT100 (low or high dose) or placebo. The study will be conducted at approximately 15-20 clinical sites in major metropolitan areas across the US. Visit http://www.thriveivf.com or http://www.clinicaltrials.gov for more information.
Shady Grove Fertility
Shady Grove Fertility is America’s largest and most progressive fertility center performing over 6,000 IVF cycles, including over 1,000 egg donation cycles, and an equal number of ovulation induction and IUI cycles annually. Twenty-eight reproductive endocrinologists as well as PhD scientists, geneticists and 480 highly specialized staff care for patients in 16 full-service offices and 5 satellite locations throughout the Philadelphia, Baltimore, and Washington, DC metropolitan areas. SGF offers a comprehensive range of fertility treatment options including Ovulation Induction, IUI, IVF, and Donor Egg as well as resources to comprehensively address patients’ needs - medical, emotional, and financial. For patient convenience IVF retrievals and transfers are now performed at three regional IVF Centers in Rockville, MD, Baltimore, MD and Chesterbrook, PA. For more information, visit http://www.shadygrovefertility.com.
About Nora Therapeutics, Inc.
Nora Therapeutics, Inc., is a specialty biopharmaceutical company focused on developing therapeutics to address unmet clinical needs in reproductive medicine. Nora’s lead compound, NT100, is being specifically designed and developed for use following in vitro fertilization (IVF) procedures to improve pregnancy success rates and outcomes. NT100 is a novel biologic agent similar to a naturally occurring protein in the female reproductive tract. NT100’s mechanism of action may better enable embryo implantation and pregnancy maintenance by optimizing maternal-fetal immune tolerance. For more information about Nora Therapeutics, visit http://www.noratherapeutics.com.